CADRENAL THERAPEUTICS INC (CVKD)

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

/PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K...

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K...

Sidoti Events, LLC's Virtual August Micro-Cap Conference

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024

CVKD stock results show that Cadrenal Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cadrenal Therapeutics (NASDAQ:CVKD) just reported results for the second quarte...

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K...

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K...

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K...

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K...

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024

CVKD stock results show that Cadrenal Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible...

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning!

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

/PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Pre-market stock movers are the perfect way to start the week as we dive into the biggest stories moving shares on Monday!

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible...

Cadrenal Therapeutics appoints Jeff Cole as COO (NASDAQ:CVKD)

Cadrenal Therapeutics appoints Jeff Cole as Chief Operating Officer to oversee manufacturing, supply chain, intellectual property, and commercialization...

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

/PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet...

Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions

/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet...

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

The biggest pre-market stock movers for Wednesday are ready to go as we break down all of the latest news moving shares today!